Food timing may shape how T cells respond to infection and therapy
A new study reveals how lipids released after a meal can durably boost T cell metabolism, translation, and…
Breakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years
Researchers report encouraging long-term results from an experimental treatment approach that rethinks the timing of cancer therapy. By…
Targeting glutamine metabolism enhances CAR-macrophage cancer therapy
Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function. Specifically,…
Trial shows durable response with preoperative immunotherapy in bowel cancer
Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before…
New roadmap links liver cancer biology to immunotherapy and precision medicine
A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona…
New biomarker predicts prognosis and treatment response in colorectal cancer
Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to establishing prognosis…
Nanomedicine offers targeted solutions for breast cancer treatment
Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.…
How the nutrient cysteine controls cancer-fighting power of T cells
A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Bloomberg School…
Study explores racial differences in gastric cancer immunotherapy outcomes
Advanced gastric cancer remains one of the deadliest malignancies, with a 5-year overall survival rate below 10%. In…
Immunotherapy plus chemotherapy improves outcomes in stage III dMMR colon cancer
A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with…
New guidance aims to standardize tumor mutational burden in cancer
Immune checkpoint inhibitors have transformed cancer care, yet only a minority of patients respond to monotherapy, and immune-related…
Blood pressure drug boosts effectiveness of cancer therapy
In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP,…